The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Open accessAbstract
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Self-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationAdipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Self-citationA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationdu Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Self-citationPujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Self-citationNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Self-citationRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Self-citationLedermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Self-citationEmerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,378
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Self-citationBuys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Self-citationAlsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Self-citationNon-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,169
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Self-citationPennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationPyClone: statistical inference of clonal population structure in cancer
Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 999
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Self-citationThe Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Self-citationAbkevich, V, Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith-McCune, K., Broaddus, R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 815
Self-citationPiek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Self-citationMeindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.569 · Cited by 743
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
Chao, M. P., Weissman, I. L., & Majeti, R. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.010 · Cited by 649
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599
Self-citationBookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Self-citationDeciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Self-citationPerets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Self-citationNorquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Self-citationNielsen, J. S., Sahota, R. A., Milne, K., Kost, S. E., Nesslinger, N. J., Watson, P. H., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0234 · Cited by 553
Self-citationGermline mutations in RAD51D confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (UK), Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G., Kalmyrzaev, B., Warren-Perry, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 534
Silva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Ginestier, C., Johnston, C., Kueck, A., Reynolds, R. K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3175 · Cited by 514
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, I. M., & Kurman, R. J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.85 · Cited by 513
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015) · The Lancet · doi:10.1016/s0140-6736(14)61687-1 · Cited by 472
Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study
Falconer, H., Yin, L., Gronberg, H., & Altman, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju410 · Cited by 436
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 430
Self-citationHarter, P., Bois, A. D., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schröder, W., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9058-0 · Cited by 425
Cheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
Self-citationBashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L. M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4230 · Cited by 421
Self-citationMutations in BRIP1 confer high risk of ovarian cancer
Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., Besenbacher, S., Lundin, P., Stacey, S. N., Gudmundsson, J., et al. (2011) · Nature Genetics · doi:10.1038/ng.955 · Cited by 406
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P. J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 400
Self-citationPrognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Konecny, G. E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K. R., Dering, J., Ginther, C., Chen, H.-W., Dowdy, S., Cliby, W., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju249 · Cited by 398
Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C. V., Zhao, Y., Reynolds, S., Cheng, H., Rupaimoole, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.020 · Cited by 394
Self-citationYeung, T.-L., Leung, C. S., Wong, K.-K., Samimi, G., Thompson, M. S., Liu, J., Zaid, T. M., Ghosh, S., Birrer, M. J., & Mok, S. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0023 · Cited by 394
Self-citationEpigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Self-citationInterleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Self-citationRamos, P., Karnezis, A. N., Craig, D. W., Sekulic, A., Russell, M. L., Hendricks, W. P. D., Corneveaux, J. J., Barrett, M. T., Shumansky, K., Yang, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.2928 · Cited by 387
Self-citationKuhn, E., Kurman, R. J., Vang, R., Sehdev, A. S., Han, G., Soslow, R., Wang, T., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3023 · Cited by 387
Alterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F., VanCriekinge, W., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 386
Cheon, D.-J., Tong, Y., Sim, M.-S., Dering, J., Berel, D., Cui, X., Lester, J., Beach, J. A., Tighiouart, M., Walts, A. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1256 · Cited by 373
Self-citationPoly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Self-citationRelationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma
Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., Chen, L., Coukos, G., & Zou, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1866 · Cited by 337
Self-citationEvaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Self-citationCD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Ye, Q., Song, D.-G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G., & Powell, D. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0945 · Cited by 322
Self-citationHematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 311
Self-citationSurvival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer
井上, 隆., Montz, F. J., Lagasse, L. D., Leuchter, R. S., & Karlan, B. Y. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5145 · Cited by 308
Self-citationMesothelial Cells Promote Early Ovarian Cancer Metastasis through Fibronectin Secretion
Kenny, H. A., Chiang, C.-Y., White, E. A., Schryver, E. M., Habis, M., Romero, I. L., Ladanyi, A., Penicka, C. V., George, J., Matlin, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74778 · Cited by 303
Self-citationOvarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Iwanicki, M. P., Davidowitz, R. A., Ng, M. R., Besser, A., Muranen, T., Merritt, M., Danuser, G., Ince, T., & Brugge, J. S. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0010 · Cited by 303
Self-citationProspective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
Harter, P., Sehouli, J., Reuß, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31820aaafd · Cited by 297
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
McAlpine, J. N., Hanley, G. E., Woo, M. M. M., Tone, A. A., Rozenberg, N., Swenerton, K. D., Gilks, C. B., Finlayson, S. J., Huntsman, D. G., & Miller, D. M. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.01.003 · Cited by 286
Self-citationModeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280
Self-citationClarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Self-citationDuraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Self-citationMukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomsky, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 270
Self-citationMorphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262
Self-citationDisparities in Ovarian Cancer Care Quality and Survival According to Race and Socioeconomic Status
Bristow, R. E., Powell, M. A., Al-Hammadi, N., Chen, L., Miller, J. P., Roland, P. Y., Mutch, D. G., & Cliby, W. A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt065 · Cited by 262
Parikh, A., Lee, C., Joseph, P., Marchini, S., Baccarini, A., Kolev, V., Romualdi, C., Fruscio, R., Shah, H., Wang, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms3977 · Cited by 258
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 253
Self-citationGermline RAD51C mutations confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (BCSC) (UK), Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M. M., Ramsay, E., Hughes, D., Warren-Perry, M., Snape, K., Eccles, D., et al. (2012) · Nature Genetics · doi:10.1038/ng.2224 · Cited by 252
Horowitz, N. S., Miller, A., Rungruang, B., Richard, S. D., Rodriguez, N., Bookman, M. A., Hamilton, C. A., Krivak, T. C., & Maxwell, G. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3106 · Cited by 252
Self-citationIdentification of six new susceptibility loci for invasive epithelial ovarian cancer
EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3185 · Cited by 250
Self-citation(2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70322-4 · Cited by 249
Trabert, B., Ness, R. B., Lo-Ciganic, W.-H., Murphy, M. A., Goode, E. L., Poole, E. M., Brinton, L. A., Webb, P. M., Nagle, C. M., Jordan, S. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt431 · Cited by 243
Self-citationAhmed, A. A., Mills, A. D., Ibrahim, A. E. K., Temple, J., Blenkiron, C., Vias, M., Massie, C. E., Iyer, N. G., McGeoch, A., Crawford, R., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.014 · Cited by 233
Self-citationPAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Laury, A. R., Hornick, J. L., Perets, R., Krane, J. F., Corson, J., Drapkin, R., & Hirsch, M. S. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181da7687 · Cited by 230
Self-citationExpression of PAX8 in Normal and Neoplastic Tissues: A Comprehensive Immunohistochemical Study
Tacha, D., Zhou, D., & Cheng, L. (2011) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0b013e3182025f66 · Cited by 226
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001200 · Cited by 225
CPTAC Assay Portal: a repository of targeted proteomic assays
the Clinical Proteomic Tumor Analysis Consortium (CPTAC), Whiteaker, J. R., Halusa, G. N., Hoofnagle, A. N., Sharma, V., MacLean, B., Yan, P., Wrobel, J. A., Kennedy, J., Mani, D. R., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3002 · Cited by 223
Inaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., Nagasaka, T., Akimoto, H., Takikawa, O., & Kikkawa, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.07.015 · Cited by 216
Karst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., Etemadmoghadam, D., Bowtell, D. D. L., & Drapkin, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2247 · Cited by 208
Self-citationCharacterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
Ince, T. A., Sousa, A. D., Jones, M. A., Harrell, J. C., Agoston, E. S., Krohn, M., Selfors, L. M., Liu, W., Chen, K., Yong, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8419 · Cited by 199
Menon, U., Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4945 · Cited by 196
Self-citationRisk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples
Riester, M., Wei, W., Waldron, L., Culhane, A. C., Trippa, L., Oliva, E., Kim, S.-H., Michor, F., Huttenhower, C., Parmigiani, G., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju048 · Cited by 195
Self-citationTumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Weroha, S. J., Becker, M. A., Enderica-Gonzalez, S., Harrington, S. C., Oberg, A. L., Maurer, M. J., Perkins, S. E., AlHilli, M., Butler, K. A., McKinstry, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2611 · Cited by 189
Self-citationβ-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids
Condello, S., Morgan, C. A., Nagdas, S., Cao, L., Turek, J., Hurley, T. D., & Matei, D. (2015) · Oncogene · doi:10.1038/onc.2014.178 · Cited by 188
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
Vecchione, A., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., Sonego, M., Cirombella, R., Onesti, E. C., Pellegrini, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305472110 · Cited by 188
Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
Zhang, S., Cui, B., Lai, H., Liu, G., Ghia, E. M., Widhopf, G. F., Zhang, Z., Wu, C. C. N., Chen, L., Wu, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419599111 · Cited by 186
Aspuria, P.-J. P., Lunt, S. Y., Väremo, L., Vergnes, L., Gozo, M., Beach, J. A., Salumbides, B., Reue, K., Wiedemeyer, W. R., Nielsen, J., et al. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-21 · Cited by 185
Self-citationGenomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Cooke, S. L., Ng, C. K. Y., Melnyk, N., Garcia, M. J., Hardcastle, T., Temple, J., Langdon, S., Huntsman, D., & Brenton, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.245 · Cited by 178
Self-citationKenny, H. A., Lal-Nag, M., White, E. A., Shen, M., Chiang, C.-Y., Mitra, A. K., Zhang, Y., Curtis, M., Schryver, E. M., Bettis, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7220 · Cited by 172
Self-citationManchanda, R., Legood, R., Burnell, M., McGuire, A., Raikou, M., Loggenberg, K., Wardle, J., Sanderson, S., Gessler, S., Side, L., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju380 · Cited by 172
Self-citationBaratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L. C., Kung, A. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422165112 · Cited by 168
Self-citationWick, D. A., Webb, J. R., Nielsen, J. S., Martin, S. D., Kroeger, D. R., Milne, K., Castellarin, M. L., Twumasi‐Boateng, K., Watson, P. H., Holt, R. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2147 · Cited by 167
Self-citationPrimary culture and immortalization of human fallopian tube secretory epithelial cells
Karst, A. M., & Drapkin, R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.097 · Cited by 163
Self-citationProphylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers
Kwon, J. S., Tinker, A., Pansegrau, G., McAlpine, J., Housty, M., McCullum, M., & Gilks, C. B. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182783c2f · Cited by 161
Epigenetic Targeting of Ovarian Cancer Stem Cells
Wang, Y., Cardenas, H., Fang, F., Condello, S., Taverna, P., Segar, M., Liu, Y., Nephew, K. P., & Matei, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1022 · Cited by 161
Self-citationMetformin intake is associated with better survival in ovarian cancer: A case‐control study
Kumar, S., Meuter, A., Thapa, P., Langstraat, C., Giri, S., Chien, J., Rattan, R., Cliby, W., & Shridhar, V. (2013) · Cancer · doi:10.1002/cncr.27706 · Cited by 160
Ovarian cancer screening—Current status, future directions
Menon, U., Griffin, M., & Gentry‐Maharaj, A. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.030 · Cited by 156
Self-citationImmunotherapy for Ovarian Cancer: What's Next?
Kandalaft, L. E., Powell, D. J., Singh, N., & Coukos, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2369 · Cited by 154
Self-citationMukhopadhyay, A., Plummer, E. R., Elattar, A., Soohoo, S., Uzir, B. F., Quinn, J. E., McCluggage, W. G., Maxwell, P., Aneke, H., Curtin, N. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0324 · Cited by 151
Self-citationSherman‐Baust, C. A., Kuhn, E., Valle, B. L., Shih, I., Kurman, R. J., Wang, T., Amano, T., Ko, M. S. H., Miyoshi, I., Araki, Y., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4353 · Cited by 147
Topp, M. D., Hartley, L., Cook, M., Heong, V. Y. M., Boehm, E., McShane, L., Pyman, J. M., McNally, O., Ananda, S. S., Harrell, M., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.008 · Cited by 145
Self-citationSong, H., Cicek, M. S., Dicks, E., Harrington, P. A., Ramus, S. J., Cunningham, J. M., Fridley, B. L., Tyrer, J. P., Alsop, J., Jimenez‐Liñan, M., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu172 · Cited by 140
Self-citationDNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Stronach, E. A., Chen, M. M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H. S., & Gabra, H. (2011) · Neoplasia · doi:10.1593/neo.111032 · Cited by 138
Self-citationMetformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models
Lengyel, E. R., Litchfield, L. M., Mitra, A. K., Nieman, K. M., Mukherjee, A., Zhang, Y., Johnson, A., Bradaric, M. J., Lee, W., & Romero, I. L. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.10.026 · Cited by 137
Self-citationMesenchymal gene program–expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance
Davidowitz, R. A., Selfors, L. M., Iwanicki, M., Elias, K. M., Karst, A. M., Piao, H., Ince, T. A., Drage, M. G., Dering, J., Konecny, G. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69815 · Cited by 137
Self-citationManchanda, R., Loggenberg, K., Sanderson, S., Burnell, M., Wardle, J., Gessler, S., Side, L., Balogun, N., Desai, R., Kumar, A., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju379 · Cited by 135
Self-citationPatient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
Ricci, F., Bizzaro, F., Cesca, M., Guffanti, F., Ganzinelli, M., Decio, A., Ghilardi, C., Perego, P., Fruscio, R., Buda, A. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0274 · Cited by 135
A framework for a personalized surgical approach to ovarian cancer
Nick, A. M., Coleman, R. L., Ramirez, P. T., & Sood, A. K. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.26 · Cited by 131
Self-citationEvaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations: Missed Opportunities
Meyer, L. A., Anderson, M. E., Lacour, R. A., Suri, A., Daniels, M. S., Urbauer, D. L., Nogueras‐González, G. M., Schmeler, K. M., Gershenson, D. M., & Lu, K. H. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181da08d7 · Cited by 128
Self-citationGermline BRCA1 and BRCA2 Mutations in Ovarian Cancer
Schrader, K. A., Hurlburt, J., Kalloger, S. E., Hansford, S., Young, S. S., Huntsman, D. D., Gilks, C. B., & McAlpine, J. N. (2012) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31825f3576 · Cited by 128
Self-citationMittag, J., Winterhager, E., Bauer, K., & Grümmer, R. (2006) · Endocrinology · doi:10.1210/en.2006-1054 · Cited by 127
Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer
Enshaei, A., Robson, C. N., & Edmondson, R. J. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4475-6 · Cited by 126
Self-citationGourley, C., McCavigan, A., Perren, T. J., Paul, J., Michie, C. O., Churchman, M., Williams, A. R. W., McCluggage, W. G., Parmar, M., Kaplan, R. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5502 · Cited by 123
Self-citationDobbin, Z. C., Katre, A. A., Steg, A. D., Erickson, B. K., Shah, M. M., Alvarez, R. D., Conner, M., Schneider, D. A., Chen, D., & Landen, C. N. (2014) · Oncotarget · doi:10.18632/oncotarget.2373 · Cited by 120
STICS SCOUTs and p53 signatures a new language for pelvic serous carcinogenesis
Crum, C. P. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e275 · Cited by 111
Evidence for a Dualistic Model of High-grade Serous Carcinoma
Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N. S., Crum, C. P., & Meserve, E. E. K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000369 · Cited by 111
Cowin, P. A., George, J., Fereday, S., Loehrer, E. A., Loo, P. V., Cullinane, C. M., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0203 · Cited by 110
Self-citationMartins, F. C., de Santiago, I., Trinh, A. C., Xian, J., Guo, A., Sayal, K., Jimenez‐Liñan, M., Deen, S., Driver, K. E., Mack, M. L., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0526-8 · Cited by 108
Self-citationEtemadmoghadam, D., George, J., Cowin, P. A., Cullinane, C. M., Kansara, M., Chenevix‐Trench, G., Gorringe, K. L., Smyth, G. K., & Bowtell, D. D. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015498 · Cited by 106
Self-citationPopulation Distribution of Lifetime Risk of Ovarian Cancer in the United States
Pearce, C. L., Stram, D. O., Ness, R. B., Stram, D. A., Roman, L. D., Templeman, C. E., Lee, A. W., Menon, U., Fasching, P. A., McAlpine, J. N., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1128 · Cited by 98
Self-citationThe Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang, F., Munck, J. M., Tang, J., Taverna, P., Wang, Y., Miller, D. F., Pilrose, J. M., Choy, G. S., Azab, M., Pawelczak, K. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1553 · Cited by 97
Self-citationMcNeish, I. A., Oza, A. M., Coleman, R. L., Scott, C. L., Konecny, G. E., Tinker, A. V., O’Malley, D. M., Brenton, J. D., Kristeleit, R. S., Bell‐McGuinn, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5508 · Cited by 93
Self-citationGeorge, J., Alsop, K., Etemadmoghadam, D., Hondow, H., Mikeska, T., Dobrovic, A., DeFazio, A., Chenevix‐Trench, G., Smyth, G. K., Levine, D. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0066 · Cited by 92
Self-citationKarst, A. M., Levanon, K., Duraisamy, S., Liu, J. F., Hirsch, M. S., Hecht, J. L., & Drapkin, R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.021 · Cited by 92
Self-citationAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Choi, H. J., Armaiz-Peña, G. N., Pradeep, S., Cho, M. S., Coleman, R. L., & Sood, A. K. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9538-9 · Cited by 92
Self-citationDIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells
Lü, Z., Baquero, M. T., Yang, H., Yang, M., Reger, A. S., Kim, C., Levine, D. A., Clarke, C. H., Liao, W. S. ‐., & Bast, R. C. (2014) · Autophagy · doi:10.4161/auto.28577 · Cited by 81
Self-citationThe Ovary Is an Alternative Site of Origin for High-Grade Serous Ovarian Cancer in Mice
Kim, J., Coffey, D. M., Ma, L., & Matzuk, M. M. (2015) · Endocrinology · doi:10.1210/en.2014-1977 · Cited by 79
Fotopoulou, C., Zang, R., Gültekin, M., Cibula, D., Ayhan, A., Liu, D., Richter, R., Braicu, E. I., Mahner, S., Harter, P., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2673-z · Cited by 77
Self-citationZaid, T., Yeung, T., Thompson, M. S., Leung, C. S., Harding, T. C., Co, N., Schmandt, R., Kwan, S.-Y., Rodriguez-Aguay, C., Lopez-Berestein, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2736 · Cited by 77
Self-citationDrescher, C. W., Shah, C., Thorpe, J. D., O'Briant, K. C., Anderson, G. L., Berg, C. D., Urban, N. D., & McIntosh, M. W. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6691 · Cited by 75
Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Kotsopoulos, J., Lubiński, J., Gronwald, J., Cybulski, C., Demsky, R., Neuhausen, S. L., Kim‐Sing, C., Tung, N., Friedman, S., Senter, L. A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29386 · Cited by 74
Self-citationTargeted anti-vascular therapies for ovarian cancer: current evidence
Hall, M., Gourley, C., McNeish, I. A., Ledermann, J. A., Gore, M. E., Jayson, G. C., Perren, T. J., Rustin, G. J. S., & Kaye, S. B. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.541 · Cited by 74
Self-citationMolecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma
Jazaeri, A. A., Bryant, J. L., Park, H., Li, H., Dahiya, N., Stoler, M. H., Ferriss, J. S., & Dutta, A. (2011) · Neoplasia · doi:10.1593/neo.11138 · Cited by 72
Low-dose aspirin use and the risk of ovarian cancer in Denmark
Baandrup, L., Kjær, S. K., Olsen, J. H., Dehlendorff, C., & Friis, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu578 · Cited by 71
Early versus delayed treatment of relapsed ovarian cancer
Rustin, G. J. S., van der Burg, M., Griffin, C. L., Qian, W., & Swart, A. M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60126-8 · Cited by 70
Ultrasound Molecular Imaging in a Human CD276 Expression–Modulated Murine Ovarian Cancer Model
Lutz, A. M., Bachawal, S. V., Drescher, C. W., Pysz, M. A., Willmann, J. K., & Gambhir, S. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1642 · Cited by 57
O'Donnell, R. L., McCormick, A., Mukhopadhyay, A., Woodhouse, L. C., Moat, M., Grundy, A., Dixon, M., Kaufman, A., Soohoo, S., Elattar, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090604 · Cited by 52
Self-citationMcKie, A. B., Vaughan, S., Zanini, E., Okon, I. S., Louis, L. S., de Sousa, C., Greene, M. I., Wang, Q., Agarwal, R., Shaposhnikov, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0256 · Cited by 52
Self-citationDecitabine reactivated pathways in platinum resistant ovarian cancer
Fang, F., Zuo, Q., Pilrose, J. M., Wang, Y., Shen, C., Li, M., Wulfridge, P., Matei, D. E., & Nephew, K. P. (2014) · Oncotarget · doi:10.18632/oncotarget.1961 · Cited by 49
Self-citationBiomarkers, the molecular gaze and the transformation of cancer survivorship
Bell, K. (2013) · BioSocieties · doi:10.1057/biosoc.2013.6 · Cited by 46
Cracking Open Window of Opportunity Trials
Kalinsky, K. M., & Hershman, D. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3293 · Cited by 37
Norquist, B. M., Pennington, K. P., Agnew, K. J., Harrell, M. I., Pennil, C. C., Lee, M. K., Casadei, S., Thornton, A., Garcia, R. L., Walsh, T., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.015 · Cited by 34
Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity
Cai, S., Wang, H., Bailey, B., Ernstberger, A., Juliar, B. E., Sinn, A. L., Chan, R. J., Jones, D. R., Mayo, L. D., Baluyut, A. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1959 · Cited by 32
Daniels, M. S., Babb, S. A., King, R. H., Urbauer, D. L., Batte, B. A. L., Brandt, A. C., Amos, C. I., Buchanan, A. H., Mutch, D. G., & Lu, K. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.6055 · Cited by 28
Self-citationMarx, V. (2015) · Nature · doi:10.1038/520389a · Cited by 22
Biopsychological Stress Factors in BRCA Mutation Carriers
Wenzel, L. B., Osann, K., Lester, J., Kurz, R. N., Hsieh, S., Nelson, E. L., & Karlan, B. Y. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.06.007 · Cited by 20
Self-citationBjörkman, A., Qvist, P., Du, L., Bartish, M., Zaravinos, A., Georgiou, K. E., Børglum, A. D., Gatti, R. A., Törngren, T., & Pan‐Hammarström, Q. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418947112 · Cited by 15
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationEpithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
The potential role of RNA N6-methyladenosine in Cancer progression
Wang, T., Kong, S., Tao, M., & Ju, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01204-7 · Cited by 1,013
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
High grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Self-citation
Metadata
- Authors
- Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., Brenton, J. D., Chiappinelli, K. B., Martins, F. C., Coukos, G., Drapkin, R., Edmondson, R., Fotopoulou, C., Gabra, H., Galon, J., Gourley, C., Heong, V., Huntsman, D. G., Iwanicki, M., Karlan, B. Y., Kaye, A., Lengyel, E., Levine, D. A., Lu, K. H., McNeish, I. A., Menon, U., Narod, S. A., Nelson, B. H., Nephew, K. P., Pharoah, P., Powell, D. J., Ramos, P., Romero, I. L., Scott, C. L., Sood, A. K., Stronach, E. A., & Balkwill, F. R.
- Venue
- Nature Reviews Cancer
- Published
- 2015-10-23
- Volume
- 15
- Issue
- 11
- Pages
- 668-679
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2111900617
- Cited by
- 1,367
- References
- 181
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.